Other prominent STIs that emerged in breast cancer treatment include everolimus, a second-generation inhibitor of the Mammalian Target of Rapamycin (mTOR) [116,117], and inhibitors of Cyclin-Dependent Kinases (CDKs) [118]. This evidence concerns the gene MTOR and breast carcinoma.